Insider Selling: Pharvaris (NASDAQ:PHVS) CFO Sells $218,820.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CFO David Nassif sold 6,000 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $36.47, for a total value of $218,820.00. Following the completion of the transaction, the chief financial officer owned 114,300 shares in the company, valued at approximately $4,168,521. This trade represents a 4.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Pharvaris Trading Down 2.9%

Shares of PHVS stock opened at $32.02 on Friday. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25. The stock has a market cap of $2.09 billion, a P/E ratio of -10.50 and a beta of -2.33. The company has a 50 day simple moving average of $35.29 and a two-hundred day simple moving average of $31.98.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. grew its stake in shares of Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Pharvaris in the 2nd quarter valued at approximately $26,677,000. Seven Fleet Capital Management LP boosted its stake in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after purchasing an additional 457,804 shares in the last quarter. Moore Capital Management LP acquired a new stake in Pharvaris in the 2nd quarter worth approximately $1,522,000. Finally, Wellington Management Group LLP increased its stake in Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on PHVS shares. Guggenheim upped their price target on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Wedbush boosted their target price on shares of Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 target price on shares of Pharvaris in a research report on Wednesday, September 9th. Leerink Partners upped their target price on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.87.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.